Candel Therapeutics (CADL) Non-Current Debt (2020 - 2025)

Candel Therapeutics (CADL) has 6 years of Non-Current Debt data on file, last reported at $1.0 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Debt fell 41.83% year-over-year to $1.0 million; the trailing twelve-month figure through Dec 2025 stood at $1.0 million (down 41.83% YoY), and the FY2025 full-year result was $1.0 million, down 41.83% from the prior year.
• Non-Current Debt grew to $1.0 million in Q4 2025, from $973000.0 in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $20.2 million in Q4 2022 to a low of $521000.0 in Q2 2021.
• A 5-year average of $6.6 million and a median of $990500.0 in 2025 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt soared 3743.76% in 2022 and plunged 96.5% in 2023, its largest moves.
• Tracing CADL's Non-Current Debt over 5 years: stood at $560000.0 in 2021, then soared by 3507.5% to $20.2 million in 2022, then tumbled by 96.28% to $751000.0 in 2023, then soared by 130.76% to $1.7 million in 2024, then tumbled by 41.83% to $1.0 million in 2025.
• Business Quant data shows CADL's Non-Current Debt at $1.0 million in Q4 2025, $973000.0 in Q3 2025, and $904000.0 in Q1 2025.